Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Polycystic Ovary Syndrome × Exercise Test × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 9 Lung Neoplasms 7 Colorectal Neoplasms 6 Prostatic Neoplasms 4 Hodgkin Disease 4 Hematologic Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Pancreatic Neoplasms 2 Obesity 2 Neoplasms 2 Multiple Myeloma 2 Motor Activity 2 Lymphoma, Non-Hodgkin 2 Hematopoietic and Lymphoid System Neoplasm 2 Gastrointestinal Diseases 2 Carcinoma, Non-Small-Cell Lung 2 Urinary Bladder Neoplasms 1 Trastuzumab Cardiotoxicity 1 Sleep Wake Disorders 1 Sedentary Behavior 1 Sarcopenia 1 Radiation Pneumonitis 1 Radiation Fibrosis Syndrome 1 Polycystic Ovary Syndrome 1 Pelvic Neoplasms 1 Pathologically Proven Gastrointestinal Malignancy 1 Oropharyngeal Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Myocardial Fibrosis 1

Interventions

Metformin 126 Clomiphene 43 Letrozole 34 Inositol 31 Folic Acid 16 Progesterone 13 Exercise 13 Chorionic Gonadotropin 13 drospirenone and ethinyl estradiol combination 12 Ethinyl Estradiol 12 Estradiol 11 Contraceptives, Oral 11 Caloric Restriction 11 cetrorelix 10 Triptorelin Pamoate 9 Cholecalciferol 9 Spironolactone 8 Pioglitazone 8 Menotropins 8 Diet 8 Tablets 7 High-Intensity Interval Training 7 Gonadotropins 7 Acupuncture Therapy 7 follitropin alfa 6 drospirenone 6 Thioctic Acid 6 Ovidrel 6 Liraglutide 6 Exenatide 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05215223 2023-10-17

WBV

Cairo University

Phase NA Completed

Insulin Resistance, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡